The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines
The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding alpha-galactosidase A (alpha-Gal A), with consequent accumulation of its major glycosphingolipid substrate, globotriaosylceramide (GL-3). Over 500 Fabry mutations have been reported; approximately 60% are missense. The iminosugar 1-deoxygalactonojirimycin (DGJ, migalastat hydrochloride, AT1001) is a pharmacological chaperone that selectively binds alpha-Gal A, increasing physical stability, lysosomal trafficking, and cellular activity. To identify DGJ-responsive mutant forms of alpha-Gal A, the effect of DGJ incubation on alpha-Gal A levels was assessed in cultured lymphoblasts from males with Fabry disease representing 75 different missense mutations, one insertion, and one splice-site mutation. Baseline alpha-Gal A levels ranged from 0 to 52% of normal. Increases in alpha-Gal A levels (1.5- to 28-fold) after continuous DGJ incubation for 5 days were seen for 49 different missense mutant forms with varying EC(50) values (820 nmol/L to >1 mmol/L). Amino acid substitutions in responsive forms were located throughout both structural domains of the enzyme. Half of the missense mutant forms associated with classic (early-onset) Fabry disease and a majority (90%) associated with later-onset Fabry disease were responsive. In cultured fibroblasts from males with Fabry disease, the responses to DGJ were comparable to those of lymphoblasts with the same mutation. Importantly, elevated GL-3 levels in responsive Fabry fibroblasts were reduced after DGJ incubation, indicating that increased mutant alpha-Gal A levels can reduce accumulated substrate. These data indicate that DGJ merits further evaluation as a treatment for patients with Fabry disease with various missense mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241 · cited 2×
“The illustrations of the three-dimensional structures were generated with SWISS-PDB viewer ( Guex and Peitsch 1997 ) and rendered with Persistence of Vision Raytracer (Version 3.6).”
MethodInfluentialThe metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Human Gene Mutation Database (HGMD®): 2003 update: HGMD 2003 UPDATE
Stenson, P. D., Ball, E. V., Mort, M., Phillips, A. D., Shiel, J. A., Thomas, N. S. T., Abeysinghe, S., Krawczak, M., & Cooper, D. N. (2003) · Human Mutation · doi:10.1002/humu.10212 · Cited by 1,829 · cited 2×
“More than 400 mutations have been reported in Fabry patients, with ~60% being missense (Human Gene Mutation Database; http://www.hgmd.org; Stenson et al 2003).”
BackgroundEnzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053 · cited 2×
“gene (GLA) that encodes the lysosomal hydrolase !-galactosidase A (!-Gal A; EC 3.2.1.22), the enzyme responsible for the catabolism of neutral glycosphingolipids with terminal !-galactosyl residues ( Brady et al 1967; Desnick et al 2001; Kint 1970).”
BackgroundInfluentialHigh Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., & Desnick, R. J. (2006) · The American Journal of Human Genetics · doi:10.1086/504601 · Cited by 1,008 · cited 2×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundSelf-citationAn Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330504 · Cited by 763 · cited 1×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundA routine method for the establishment of permanent growing lymphoblastoid cell lines
Neitzel, H. (1986) · Human Genetics · doi:10.1007/bf00279094 · Cited by 644 · cited 2×
“…R301Q) were immortalized and established by phytohaemagglutininstimulated Epstein–Barr virus transformation of peripheral blood mononuclear cells (Neitzel 1986) using blood samples obtained from clinical investigators; five lymphoblast lines (E66Q, A97V, M296I, Q279E, and g9331G>A) were from Dr…”
MethodFan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614 · cited 10×
“-Gal A protein levels and total enzymatic activity as measured in cell lysates (Asano et al 2000; Fan et al 1999; Yam et al 2005, 2006).”
BackgroundMethodResultInfluentialPrevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy
Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W. J., & Elliott, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000012626.81324.38 · Cited by 570 · cited 1×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundFabry's Disease: Alpha-Galactosidase Deficiency
Kint, J. A. (1970) · Science · doi:10.1126/science.167.3922.1268 · Cited by 470 · cited 2×
“22), the enzyme responsible for the catabolism of neutral glycosphingolipids with terminal !-galactosyl residues (Brady et al 1967; Desnick et al 2001; Kint 1970).”
BackgroundPrevalence of Fabry disease in patients with cryptogenic stroke: a prospective study
Rolfs, A., Böttcher, T., Zschiesche, M., Morris, P., Winchester, B., Bauer, P., Walter, U., Mix, E., Löhr, M., Harzer, K., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67635-0 · Cited by 464 · cited 2×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundBRANTON, M. H., SCHIFFMANN, R., SABNIS, S. G., MURRAY, G. J., QUIRK, J. M., ALTARESCU, G., GOLDFARB, L., BRADY, R. O., BALOW, J. E., AUSTIN, H. A., et al. (2002) · Medicine · doi:10.1097/00005792-200203000-00003 · Cited by 461 · cited 1×
“-Gal A levels (Branton et al 2002; Desnick et al 2001).”
Nakao, S., Kodama, C., Takenaka, T., Tanaka, A., Yasumoto, Y., Yoshida, A., Kanzaki, T., Enriquez, A. L. D., Eng, C. M., Tanaka, H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00160.x · Cited by 436 · cited 1×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundSelf-citationThe Molecular Defect Leading to Fabry Disease: Structure of Human α-Galactosidase
Garman, S. C., & Garboczi, D. N. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.035 · Cited by 399 · cited 11×
“8-barrel containing the active site pocket and an anti-parallel "-sheet (Garman and Garboczi 2004).”
BackgroundInfluentialAn Atypical Variant of Fabry's Disease with Manifestations Confined to the Myocardium
Scheidt, W. V., Eng, C. M., Fitzmaurice, T. F., Erdmann, E., Hübner, G., Olsen, E. G. J., Christomanou, H., Kandolf, R., Bishop, D. F., & Desnick, R. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102073240607 · Cited by 371 · cited 1×
“-Gal A lead to reduced cellular enzyme activity as a result of lowered catalytic activity, improper folding, decreased enzyme stability, and/or inefficient trafficking to the lysosome (Bishop et al 1981; Lemansky et al 1987; von Scheidt et al 1991).”
BackgroundSelf-citationPrevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy
Monserrat, L., Gimeno-Blanes, J. R., Marín, F., Hermida-Prieto, M., García-Honrubia, A., Pérez, I., Fernández, X., de Nicolas, R., de la Morena, G., Payá, E., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.062 · Cited by 291 · cited 1×
“Furthermore, the incidence of undiagnosed Fabry disease may be even higher among patients with hypertrophic cardiomyopathy, cryptogenic stroke, and end-stage renal disease (Kotanko et al 2004; Monserrat et al 2007; Rolfs et al 2005).”
BackgroundPrevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy
Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., Maseri, A., & Frustaci, A. (2004) · Circulation · doi:10.1161/01.cir.0000139847.74101.03 · Cited by 271 · cited 1×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundAsano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O. R., & Fan, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01457.x · Cited by 242 · cited 2×
“-Gal A (Asano et al 2000; Fan et al 1999; Ishii et al 2007; Shin et al 2007, 2008).”
MethodA contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity
Fan, J.-Q. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00158-5 · Cited by 232 · cited 4×
“-Gal A that has been shown to bind to the active site of the enzyme and improve folding, stability, and lysosomal trafficking in cultured cells from males with Fabry disease (Fan 2003; Fan et al 1999; Yam et al 2005, 2006).”
BackgroundInfluentialMayes, J. S., Scheerer, J. B., Sifers, R. N., & Donaldson, M. L. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90384-3 · Cited by 218 · cited 2×
“GalNAc was included as an inhibitor for !-N-acetylgalactosaminidase, a lysosomal enzyme present in the lysates that is moderately active as an !-galactosidase and has been shown to hydrolyse the 4-MUG substrate ( Mayes et al 1981 ).”
BackgroundResults of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients
Kotanko, P., Kramar, R., Devrnja, D., Paschke, E., Voigtla[Combining Diaeresis]nder, T., Auinger, M., Demmelbauer, K., Lorenz, M., Hauser, A.-C., Kofler, H.-J. D., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000124671.61963.1e · Cited by 199 · cited 2×
“gene (GLA) that encodes the lysosomal hydrolase !-galactosidase A (!-Gal A; EC 3.2.1.22), the enzyme responsible for the catabolism of neutral glycosphingolipids with terminal !-galactosyl residues (Brady et al 1967; Desnick et al 2001; Kint 1970 ).”
BackgroundInfluentialYam, G. H.-F., Zuber, C., & Roth, J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2375com · Cited by 163 · cited 20×
“Similarly, incubation with DGJ increased !-Gal A immunofluorescence that co-localized with the lysosomal marker LAMP-1 ( Yam et al 2005 ).”
BackgroundMethodResultInfluentialIshii, S., Chang, H., Kawasaki, K., Yasuda, K., Wu, H., Garman, S. C., & Fan, J. (2007) · Biochemical Journal · doi:10.1042/bj20070479 · Cited by 147 · cited 2×
“In addition, accumulation of mutant !-Gal A enzyme in the ER may lead to cellular stress, which may also contribute to further cellular dysfunction and disease ( Ishii et al 1996 ).”
BackgroundSelf-citationShabbeer, J., Yasuda, M., Benson, S. D., & Desnick, R. J. (2006) · Human Genomics · doi:10.1186/1479-7364-2-5-297 · Cited by 144 · cited 1×
“…located within either the enzyme active-site, potentially directly disrupting catalytic ability, or the hydrophobic core, which might disrupt hydrophobic packing with detrimental effects on enzyme folding and thermodynamic stability (Garman 2007; Matsuzawa et al 2005; Shabbeer et al 2006).”
BackgroundSelf-citationIoannou, Y. A., Bishop, D. F., & Desnick, R. J. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.5.1137 · Cited by 134 · cited 1×
“-Gal A is a homodimeric glycoprotein with a molecular mass of 101 kDa (Ioannou et al 1992, 1998).”
BackgroundSelf-citationYam, G. H., Bosshard, N. U., Zuber, C., Steinmann, B. U., & Roth, J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00426.2005 · Cited by 133 · cited 16×
“-Gal A protein levels and total enzymatic activity as measured in cell lysates (Asano et al 2000; Fan et al 1999; Yam et al 2005, 2006).”
BackgroundMethodResultInfluentialCellular and tissue localization of globotriaosylceramide in Fabry disease
Askari, H., Kaneski, C. R., Semino‐Mora, C., Desai, P., Ang, A. L., Kleiner, D. E., Perlee, L. T., Quezado, M., Spollen, L. E., Wustman, B. A., et al. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0468-6 · Cited by 113 · cited 1×
“Consequently, GL-3 accumulation in tissue lysosomes as well as non-lysosomal compartments (Askari et al 2007) leads to the disease pathology.”
BackgroundSelf-citationHuman α-galactosidase A: glycosylation site 3 is essential for enzyme solubility
Ioannou, Y. A., Zeidner, K. M., Grace, M., & Desnick, R. J. (1998) · Biochemical Journal · doi:10.1042/bj3320789 · Cited by 104 · cited 1×
“-Gal A is a homodimeric glycoprotein with a molecular mass of 101 kDa (Ioannou et al 1992, 1998).”
BackgroundSelf-citationLemansky, P., Bishop, D. F., Desnick, R. J., Hasilík, A., & FIGURA, K. V. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61618-7 · Cited by 102 · cited 2×
“-Gal A lead to reduced cellular enzyme activity as a result of lowered catalytic activity, improper folding, decreased enzyme stability, and/or inefficient trafficking to the lysosome (Bishop et al 1981; Lemansky et al 1987; von Scheidt et al 1991).”
BackgroundSelf-citationGalactose Stabilizes Various Missense Mutants of α-Galactosidase in Fabry Disease
Okumiya, T., Ishii, S., Takenaka, T., Kase, R., Kamei, S., Sakuraba, H., & Suzuki, Y. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2416 · Cited by 101 · cited 1×
“For two additional cell lines reconfirmation was not performed because the original sequence determination (H46Y) or the identity of the mutation in the same lymphoblast line (Q279E) was already published (Okumiya et al 1995; Shabbeer et al 2002).”
BackgroundStructure–function relationships in α‐galactosidase A
Garman, S. C. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00198.x · Cited by 91 · cited 2×
“…located within either the enzyme active-site, potentially directly disrupting catalytic ability, or the hydrophobic core, which might disrupt hydrophobic packing with detrimental effects on enzyme folding and thermodynamic stability (Garman 2007; Matsuzawa et al 2005; Shabbeer et al 2006).”
BackgroundFabry disease: 45 novel mutations in the α-galactosidase A gene causing the classical phenotype
Shabbeer, J., Yasuda, M., Luca, E., & Desnick, R. J. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00012-4 · Cited by 91 · cited 1×
“For two additional cell lines reconfirmation was not performed because the original sequence determination (H46Y) or the identity of the mutation in the same lymphoblast line (Q279E) was already published (Okumiya et al 1995; Shabbeer et al 2002).”
BackgroundSelf-citationDammann, O. (2006) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00097.x · Cited by 71
Fabry Disease in Patients with End-Stage Renal Failure: The Potential Benefits of Screening
Bekri, S., Enica, A., Ghafari, T., Plaza, G., Champenois, I., Choukroun, G. J., Unwin, R. J., & Jaeger, P. (2005) · Nephron Clinical Practice · doi:10.1159/000085709 · Cited by 60 · cited 1×
“These patients have been identified in haemodialysis, cardiac, and stroke clinics (Bekri et al 2005; Chimenti et al 2004; Nakao et al 1995, 2003; Rolfs et al 2005; Sachdev et al 2002; Spada et al 2006).”
BackgroundMatsuzawa, F., Aikawa, S., Doi, H., Okumiya, T., & Sakuraba, H. (2005) · Human Genetics · doi:10.1007/s00439-005-1300-5 · Cited by 55 · cited 2×
“…located within either the enzyme active-site, potentially directly disrupting catalytic ability, or the hydrophobic core, which might disrupt hydrophobic packing with detrimental effects on enzyme folding and thermodynamic stability (Garman 2007; Matsuzawa et al 2005; Shabbeer et al 2006).”
BackgroundScreening for pharmacological chaperones in Fabry disease
Shin, S., Murray, G. J., Kluepfel-Stahl, S., Cooney, A. M., Quirk, J. M., Schiffmann, R., Brady, R. O., & Kaneski, C. R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.082 · Cited by 53 · cited 1×
“-Gal A (Asano et al 2000; Fan et al 1999; Ishii et al 2007; Shin et al 2007, 2008).”
Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum
Ishii, S., Kase, R., Okumiya, T., Sakuraba, H., & Suzuki, Y. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0486 · Cited by 47 · cited 1×
“-Gal A enzyme in the ER may lead to cellular stress, which may also contribute to further cellular dysfunction and disease (Ishii et al 1996).”
BackgroundPrediction of response of mutated alpha-galactosidase A to a pharmacological chaperone
Shin, S. H., Kluepfel-Stahl, S., Cooney, A. M., Kaneski, C. R., Quirk, J. M., Schiffmann, R., Brady, R. O., & Murray, G. J. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830500f4 · Cited by 43 · cited 1×
“-Gal A (Asano et al 2000; Fan et al 1999; Ishii et al 2007; Shin et al 2007, 2008).”
Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease
Ishii, S., Chang, H., Yoshioka, H., Shimada, T., Mannen, K., Higuchi, Y., Taguchi, A., & Fan, J. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149054 · Cited by 39 · cited 2×
“-Gal A levels and substrate turnover in different cell types and tissues (Ishii et al 2009; Khanna et al 2008).”
BackgroundSelf-citationFabry disease: an asymptomatic hemizygote with significant residual α-galactosidase A activity.
Bishop, D. F. (1981) · The American Journal of Human Genetics · Cited by 16
Sala-Planell, E., Latorre, J., Marinello, J., Rutllant, M. L., Miralles, J., & Avellano, R. R. D. (1981) · PubMed · Cited by 2
Research works printed but not linked: 2
- Khanna R, 2007, A levels in vitro, in vivo and in healthy volunteers. Abstract 2250/W. Presented at the American Society of Human Genetics Conference, 2007
- Schiffmann R, 2008, Abstract 768/T. Presented at the American Society of Human Genetics Conference, 2008
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
“DGJ may be effective only in patients with specific, “responsive” GLA mutations coding for a mutant a-galactosidase with enhancable residual enzyme activity [419,424].”
BackgroundPastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Self-citationGuerriero, C. J., & Brodsky, J. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00027.2011 · Cited by 418
Metadata
- Authors
- Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., Lockhart, D. J., & Valenzano, K. J.
- Affiliations
- Amicus Therapeutics (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Benjamin, E. R.
- ORCID
- Desnick, R. J.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2009-04-18
- Volume
- 32
- Issue
- 3
- Pages
- 424-440
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2058754026
- Cited by
- 173
- References
- 43
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 8 · 2020: 17 · 2019: 9 · 2018: 15 · 2017: 3 · 2016: 13 · 2015: 6 · 2014: 6 · 2013: 11 · 2012: 11
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Fabry disease, alpha-galactosidase A, 1-deoxygalactonojirimycin, migalastat, pharmacological chaperones, missense mutations, globotriaosylceramide, lysosomal storage disease, enzyme stability, fibroblasts, lymphoblasts, substrate reduction
- MeSH terms
- alpha-Galactosidase, Fabry Disease, Cell Line, Drug Evaluation, Preclinical, Enzyme Activation, Fibroblasts, Half-Life, Humans, Lymphocytes, Male, Models, Molecular, Up-Regulation, 1-Deoxynojirimycin, Molecular Chaperones, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.